エリスロポエチン（EPO）の世界市場レポート 2025年

エリスロポエチン（EPO）の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR12.6％で309億2,000万米ドルに成長します。予測期間の成長は、市場競争とバイオシミラーの影響、疾病の流行予測、ヘルスケア政策と償還の変化、新興市場の成長、臨床試験と研究の焦点に起因すると考えられます。予測期間の主な動向には、サプライチェーン管理、世界展開と新興市場、患者教育と意識向上、償還政策、市場統合と合併などがあります。

慢性腎臓病の有病率の増加は、今後数年間、エリスロポエチン市場の需要を牽引すると予想されます。慢性腎臓病患者の増加は、赤血球の産生を刺激し免疫力を高めるために使用されるエリスロポエチンの投与を必要とします。例えば、米国を拠点とする連邦政府機関である疾病管理センターは、2023年に米国成人の約14％、約3,550万人が慢性腎臓病（CKD）に罹患していると推定しています。したがって、慢性腎臓病の罹患率の増加がエリスロポエチンの需要を押し上げ、市場の収益を増加させています。

血液がんの罹患率の増加は、将来エリスロポエチン市場の成長を促進すると予測されています。血液がんとは、血液に由来し、血液、骨髄、リンパ系に影響を与えるがんのカテゴリーを指し、白血病、リンパ腫、骨髄腫などの疾患が含まれます。エリスロポエチン（EPO）は、赤血球の産生を刺激することにより、がんに関連した貧血の管理に重要な役割を果たしており、がん患者、特に化学療法を受けている患者の貧血を緩和するのに役立っています。例えば、2023年、米国を拠点とするがん撲滅を目的とする任意団体である米国がん協会は、白血病が5万9,610人の米国人を罹患させ、2万3,710人の死亡につながると推定しています。さらに、非ホジキンリンパ腫の新規症例は米国で8万550人に影響を与え、2万180人が死亡すると予想されています。したがって、血液がんの有病率の増加がエリスロポエチン市場を前進させています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界エリスロポエチン（EPO） PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のエリスロポエチン（EPO）市場：成長率分析
• 世界のエリスロポエチン（EPO）市場の実績：規模と成長, 2019-2024
• 世界のエリスロポエチン（EPO）市場の予測：規模と成長, 2024-2029, 2034F
• 世界エリスロポエチン（EPO）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のエリスロポエチン（EPO）市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• エポエチンアルファ
• エポエチンベータ
• ダルベポエチンアルファ
• その他の製品
• 世界のエリスロポエチン（EPO）市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 生物学者
• バイオシミラー
• 世界のエリスロポエチン（EPO）市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• がん
• 血液学
• 腎臓疾患
• 神経学
• その他の用途
• 世界のエリスロポエチン（EPO）市場エポエチンアルファのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• エポエチンアルファ
• エポエチンアルファバイオシミラー
• 世界のエリスロポエチン（EPO）市場エポエチンベータのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• エポエチンベータ
• エポエチンベータバイオシミラー
• 世界のエリスロポエチン（EPO）市場、ダルベポエチンアルファのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ダルベポエチンアルファ
• ダルベポエチンアルファバイオシミラー
• 世界のエリスロポエチン（EPO）市場、その他の製品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ペギネサチド
• その他の新規EPO製品

第7章 地域別・国別分析

• 世界のエリスロポエチン（EPO）市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のエリスロポエチン（EPO）市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• エリスロポエチン（EPO）市場：競合情勢
• エリスロポエチン（EPO）市場：企業プロファイル
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• 3SBio Inc.
• Celltrion Inc.
• Intas Pharmaceuticals Ltd.
• Boehringer Ingelheim GmbH
• Dr. Reddy's Laboratories Ltd.
• Sun Pharmaceutical Industries Ltd.
• Reliance Life Sciences Pvt. Ltd.
• Biocon Limited
• Chugai Pharmaceutical Co.
• Kyowa Kirin Co. Ltd.
• Apotex Inc.
• CJ Healthcare Corp.
• STADA Arzneimittel AG
• Hospira Inc.
• Sandoz International GmbH

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• エリスロポエチン（EPO）市場2029：新たな機会を提供する国
• エリスロポエチン（EPO）市場2029：新たな機会を提供するセグメント
• エリスロポエチン（EPO）市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Erythropoietin (EPO) is a glycoprotein hormone naturally produced by the peritubular cells of the kidney, stimulating the production of red blood cells. It is utilized in the treatment of anemia, a condition characterized by a shortage of red blood cells. Symptoms of anemia, such as weakness, fatigue, and shortness of breath, arise due to the crucial role of red blood cells in delivering oxygen to tissues and organs.

The primary types of erythropoietin products include epoetin-alfa, epoetin-beta, darbepoetin-alfa, and others. Epoetin alfa is a recombinant DNA-derived human erythropoietin that is synthesized in cell culture. Erythropoietin falls into different drug classes, including biologics and biosimilars, and finds applications in various medical fields such as cancer, hematology, renal diseases, neurology, and others.

The erythropoietin (EPO) market research report is one of a series of new reports from The Business Research Company that provides erythropoietin (EPO) market statistics, including erythropoietin (EPO) industry global market size, regional shares, competitors with an erythropoietin (EPO) market share, detailed erythropoietin (EPO) market segments, market trends and opportunities, and any further data you may need to thrive in the erythropoietin (EPO) industry. This erythropoietin (EPO) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The erythropoietin (EPO) market size has grown rapidly in recent years. It will grow from $17.29 billion in 2024 to $19.25 billion in 2025 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to patient education and awareness, pharmaceutical industry consolidation, healthcare reimbursement policies, market expansion and demand growth, patent expiration and biosimilar entry.

The erythropoietin (EPO) market size is expected to see rapid growth in the next few years. It will grow to $30.92 billion in 2029 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to market competition and biosimilar impact, disease prevalence projections, healthcare policy and reimbursement changes, emerging markets growth, clinical trials and research focus. Major trends in the forecast period include supply chain management, global expansion and emerging markets, patient education and awareness, reimbursement policies, market consolidation and mergers.

The increasing prevalence of chronic kidney diseases is expected to drive the demand for the erythropoietin market in the coming years. The rise in chronic kidney disease cases necessitates the administration of erythropoietin, which is used to stimulate the production of red blood cells and enhance immunity. For example, in 2023, the Centers for Disease Control, a U.S.-based federal agency, estimated that approximately 14% of U.S. adults-around 35.5 million individuals-suffer from chronic kidney disease (CKD). Thus, the growing incidence of chronic kidney diseases is boosting the demand for erythropoietin, subsequently increasing market revenues.

The rising incidence of hematologic cancer is projected to drive the growth of the erythropoietin market in the future. Hematologic cancer refers to a category of cancers that originate in the blood and impact the blood, bone marrow, and lymphatic system, including diseases such as leukemia, lymphoma, and myeloma. Erythropoietin (EPO) plays a crucial role in managing cancer-related anemia by stimulating the production of red blood cells, which helps alleviate anemia in cancer patients, especially those undergoing chemotherapy. For instance, in 2023, the American Cancer Society, a U.S.-based voluntary health organization dedicated to eliminating cancer, estimated that leukemia would affect 59,610 Americans and lead to 23,710 deaths. Additionally, new cases of non-Hodgkin lymphoma are expected to impact 80,550 individuals in the United States, resulting in 20,180 deaths. Therefore, the increasing prevalence of hematologic cancers is advancing the erythropoietin market.

Major companies in the erythropoietin market are concentrating on introducing oral medications that provide more convenient alternatives to traditional injectable therapies. This approach aims to enhance patient comfort, compliance, and treatment flexibility, particularly for individuals dealing with chronic conditions such as anemia in chronic kidney disease (CKD). For example, in February 2023, GlaxoSmithKline (GSK), a UK-based multinational pharmaceutical and biotechnology firm, launched Jesduvroq (daprodustat) tablets. This oral medication aids in increasing erythropoietin levels to help manage anemia in CKD patients by maintaining hemoglobin levels within a target range. The primary goal of Jesduvroq is to offer a more convenient alternative to injectable therapies, thereby improving patient comfort, compliance, and treatment flexibility for dialysis patients.

Major players in the erythropoietin market are innovating with products such as Varenzin-CA1 to solidify their market position. Varenzin-CA1 (molidustat oral suspension) is a conditionally approved drug by the FDA designed to manage nonregenerative anemia associated with chronic kidney disease (CKD) in cats. Elanco, a US-based pharmaceutical company, secured FDA approval for Varenzin-CA1 in May 2023. This breakthrough innovation for cats boasts a unique mode of action that triggers the genetic transcription of erythropoietin (EPO), leading to increased EPO and red blood cell production in a cat's body. Varenzin-CA1 sets a new standard of care for cats experiencing nonregenerative anemia due to CKD, offering convenience for at-home use.

Major companies operating in the erythropoietin (EPO) market include Amgen Inc., Roche Holding AG, Pfizer Inc., Merck & Co., Teva Pharmaceutical Industries Ltd., 3SBio Inc., Celltrion Inc., Intas Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Reliance Life Sciences Pvt. Ltd., Biocon Limited, Chugai Pharmaceutical Co., Kyowa Kirin Co. Ltd., Apotex Inc., CJ Healthcare Corp., STADA Arzneimittel AG, Hospira Inc., Sandoz International GmbH, Torrent Pharmaceuticals Ltd., LG Life Sciences Ltd., Sanofi S.A., Bayer AG, Hikma Pharmaceuticals.

North America was the largest region in the erythropoietin (EPO) market in 2024. The Middle East is expected to be the fastest growing region in the global erythropoietin (EPO) market analysis in the forecast period. The regions covered in the erythropoietin (epo) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the erythropoietin (epo) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The erythropoietin market consists of sales of epoetin, darbepoetin, and methoxy polyethylene glycol-epoetin beta. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Erythropoietin (EPO) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on erythropoietin (epo) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for erythropoietin (epo) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The erythropoietin (epo) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Epoetin-alfa; Epoetin-beta; Darbepoetin-alfa; Other Products
• 2) By Drug Class: Biologist; Biosimilar
• 3) By Application: Cancer; Hematology; Renal Diseases; Neurology; Other Applications
• Subsegments:
• 1) By Epoetin-Alfa: Epoetin-Alfa; Epoetin-Alfa Biosimilars
• 2) By Epoetin-Beta: Epoetin-Beta; Epoetin-Beta Biosimilars
• 3) By Darbepoetin-Alfa: Darbepoetin-Alfa; Darbepoetin-Alfa Biosimilars
• 4) By Other Products: Peginesatide; Other Novel EPO Products
• Companies Mentioned: Amgen Inc.; Roche Holding AG; Pfizer Inc.; Merck & Co.; Teva Pharmaceutical Industries Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Erythropoietin (EPO) Market Characteristics

3. Erythropoietin (EPO) Market Trends And Strategies

4. Erythropoietin (EPO) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Erythropoietin (EPO) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Erythropoietin (EPO) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Erythropoietin (EPO) Market Growth Rate Analysis
• 5.4. Global Erythropoietin (EPO) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Erythropoietin (EPO) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Erythropoietin (EPO) Total Addressable Market (TAM)

6. Erythropoietin (EPO) Market Segmentation

• 6.1. Global Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Epoetin-alfa
• Epoetin-beta
• Darbepoetin-alfa
• Other Products
• 6.2. Global Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biologist
• Biosimilar
• 6.3. Global Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cancer
• Hematology
• Renal Diseases
• Neurology
• Other Applications
• 6.4. Global Erythropoietin (EPO) Market, Sub-Segmentation Of Epoetin-Alfa, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Epoetin-Alfa
• Epoetin-Alfa Biosimilars
• 6.5. Global Erythropoietin (EPO) Market, Sub-Segmentation Of Epoetin-Beta, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Epoetin-Beta
• Epoetin-Beta Biosimilars
• 6.6. Global Erythropoietin (EPO) Market, Sub-Segmentation Of Darbepoetin-Alfa, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Darbepoetin-Alfa
• Darbepoetin-Alfa Biosimilars
• 6.7. Global Erythropoietin (EPO) Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Peginesatide
• Other Novel EPO Products

7. Erythropoietin (EPO) Market Regional And Country Analysis

• 7.1. Global Erythropoietin (EPO) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Erythropoietin (EPO) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Erythropoietin (EPO) Market

• 8.1. Asia-Pacific Erythropoietin (EPO) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Erythropoietin (EPO) Market

• 9.1. China Erythropoietin (EPO) Market Overview
• 9.2. China Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Erythropoietin (EPO) Market

• 10.1. India Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Erythropoietin (EPO) Market

• 11.1. Japan Erythropoietin (EPO) Market Overview
• 11.2. Japan Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Erythropoietin (EPO) Market

• 12.1. Australia Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Erythropoietin (EPO) Market

• 13.1. Indonesia Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Erythropoietin (EPO) Market

• 14.1. South Korea Erythropoietin (EPO) Market Overview
• 14.2. South Korea Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Erythropoietin (EPO) Market

• 15.1. Western Europe Erythropoietin (EPO) Market Overview
• 15.2. Western Europe Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Erythropoietin (EPO) Market

• 16.1. UK Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Erythropoietin (EPO) Market

• 17.1. Germany Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Erythropoietin (EPO) Market

• 18.1. France Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Erythropoietin (EPO) Market

• 19.1. Italy Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Erythropoietin (EPO) Market

• 20.1. Spain Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Erythropoietin (EPO) Market

• 21.1. Eastern Europe Erythropoietin (EPO) Market Overview
• 21.2. Eastern Europe Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Erythropoietin (EPO) Market

• 22.1. Russia Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Erythropoietin (EPO) Market

• 23.1. North America Erythropoietin (EPO) Market Overview
• 23.2. North America Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Erythropoietin (EPO) Market

• 24.1. USA Erythropoietin (EPO) Market Overview
• 24.2. USA Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Erythropoietin (EPO) Market

• 25.1. Canada Erythropoietin (EPO) Market Overview
• 25.2. Canada Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Erythropoietin (EPO) Market

• 26.1. South America Erythropoietin (EPO) Market Overview
• 26.2. South America Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Erythropoietin (EPO) Market

• 27.1. Brazil Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Erythropoietin (EPO) Market

• 28.1. Middle East Erythropoietin (EPO) Market Overview
• 28.2. Middle East Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Erythropoietin (EPO) Market

• 29.1. Africa Erythropoietin (EPO) Market Overview
• 29.2. Africa Erythropoietin (EPO) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Erythropoietin (EPO) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Erythropoietin (EPO) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Erythropoietin (EPO) Market Competitive Landscape And Company Profiles

• 30.1. Erythropoietin (EPO) Market Competitive Landscape
• 30.2. Erythropoietin (EPO) Market Company Profiles
  • 30.2.1. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Erythropoietin (EPO) Market Other Major And Innovative Companies

• 31.1. 3SBio Inc.
• 31.2. Celltrion Inc.
• 31.3. Intas Pharmaceuticals Ltd.
• 31.4. Boehringer Ingelheim GmbH
• 31.5. Dr. Reddy's Laboratories Ltd.
• 31.6. Sun Pharmaceutical Industries Ltd.
• 31.7. Reliance Life Sciences Pvt. Ltd.
• 31.8. Biocon Limited
• 31.9. Chugai Pharmaceutical Co.
• 31.10. Kyowa Kirin Co. Ltd.
• 31.11. Apotex Inc.
• 31.12. CJ Healthcare Corp.
• 31.13. STADA Arzneimittel AG
• 31.14. Hospira Inc.
• 31.15. Sandoz International GmbH

32. Global Erythropoietin (EPO) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Erythropoietin (EPO) Market

34. Recent Developments In The Erythropoietin (EPO) Market

35. Erythropoietin (EPO) Market High Potential Countries, Segments and Strategies

• 35.1 Erythropoietin (EPO) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Erythropoietin (EPO) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Erythropoietin (EPO) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer